Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>Amgen's diversified portfolio, with 17 products annualizing over $1 billion in sales, provides a stable revenue base to offset patent expirations and fund future growth.</li>
  <li>The recent $27.8 billion acquisition of Horizon Therapeutics significantly strengthens Amgen's position in the high-growth rare disease market, adding key products like Tepezza and Krystexxa.</li>
  <li>Future growth is heavily reliant on the success of its late-stage pipeline, particularly the obesity candidate MariTide, which is entering a highly competitive market, and the continued expansion of its robust biosimilars business.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Amgen's diversified portfolio, with 17 products annualizing over $1 billion in sales, provides a stable revenue base to offset patent expirations and fund future growth.
  The recent $27.8 billion acquisition of Horizon Therapeutics significantly strengthens Amgen's position in the high-growth rare disease market, adding key products like Tepezza and Krystexxa.
  Future growth is heavily reliant on the success of its late-stage pipeline, particularly the obesity candidate MariTide, which is entering a highly competitive market, and the continued expansion of its robust biosimilars business.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

Technology Select Sector SPDR / Technical Analysis

<ul>
<li>We are cautious on Nasdaq 100 (QQQ) and A.I./Technology areas (XLK, SOXX, CHAT, DRAM);</li>
<li>Gaps from August 12th and August 4th have been filled on Technology (XLK), semiconductors (SOXX, SMH), generative A.I. (CHAT), neoclouds (NCLD), and momentum (MTUM), which is a concerning development.</li>
<li>Outside of A.I. areas, the market appears healthy; the equal-weighted S&amp;P 500 (RSP) is resuming its leadership status with support at the 20-day MA.</li>
</ul>


We are cautious on Nasdaq 100 (QQQ) and A.I./Technology areas (XLK, SOXX, CHAT, DRAM);
Gaps from August 12th and August 4th have been filled on Technology (XLK), semiconductors (SOXX, SMH), generative A.I. (CHAT), neoclouds (NCLD), and momentum (MTUM), which is a concerning development.
Outside of A.I. areas, the market appears healthy; the equal-weighted S&amp;P 500 (RSP) is resuming its leadership status with support at the 20-day MA.


Downgrading Technology; Upgrading Energy and Health Care to Overweight; Caution Within A.I. Names

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>Amgen has reignited investor interest in the obesity drug space with its latest update on MariTide, a GLP-1 agonist that could reshape the competitive dynamics currently dominated by Eli Lilly and Novo Nordisk.</li><li>In a Phase 2 study, MariTide helped patients maintain 17% to 18% weight loss into the second year—levels on par with current market leaders.</li><li>However, Amgen is positioning MariTide as a superior offering with a differentiated edge: the potential for less frequent dosing—monthly or even quarterly—compared to the weekly injections required for Lilly and Novo’s therapies.</li></ul>

Amgen has reignited investor interest in the obesity drug space with its latest update on MariTide, a GLP-1 agonist that could reshape the competitive dynamics currently dominated by Eli Lilly and Novo Nordisk.In a Phase 2 study, MariTide helped patients maintain 17% to 18% weight loss into the second year—levels on par with current market leaders.However, Amgen is positioning MariTide as a superior offering with a differentiated edge: the potential for less frequent dosing—monthly or even quarterly—compared to the weekly injections required for Lilly and Novo’s therapies.

Amgen’s Obesity Drug May Crush Novo Nordisk & Lilly With Just Four Shots A Year!

<ul><li>Amgen Inc. has taken a bold step into the oncology innovation frontier with its acquisition of UK-based Dark Blue Therapeutics, a private biotech firm advancing small molecule-targeted protein degraders, in a deal worth up to $840 million.</li><li>The move, announced on January 6, 2026, aims to expand Amgen’s investigational portfolio with a compound targeting MLLT1/3—two proteins implicated in the progression of acute myeloid leukemia (AML), one of the most aggressive blood cancers.</li><li>This acquisition underscores Amgen’s intensified focus on early-stage oncology assets that leverage novel therapeutic mechanisms.</li></ul>

Amgen Inc. has taken a bold step into the oncology innovation frontier with its acquisition of UK-based Dark Blue Therapeutics, a private biotech firm advancing small molecule-targeted protein degraders, in a deal worth up to $840 million.The move, announced on January 6, 2026, aims to expand Amgen’s investigational portfolio with a compound targeting MLLT1/3—two proteins implicated in the progression of acute myeloid leukemia (AML), one of the most aggressive blood cancers.This acquisition underscores Amgen’s intensified focus on early-stage oncology assets that leverage novel therapeutic mechanisms.

Amgen Quietly Acquires UK Biotech—Is This a Pipeline Power Play?

<ul><li>Amgen reported notable financial results for Q3 2025 with revenue growth of 12% year-over-year, reaching $9.6 billion.</li><li>The company's volume growth was strong at 14%, reflecting increasing demand for its medicines amidst declining selling prices in the industry.</li><li>Several key products, including Repatha, EVENITY, and TEZSPIRE, contributed to the growth, with 16 products achieving double-digit sales increases and 14 products surpassing $1 billion in annualized sales.</li></ul>

Amgen reported notable financial results for Q3 2025 with revenue growth of 12% year-over-year, reaching $9.6 billion.The company's volume growth was strong at 14%, reflecting increasing demand for its medicines amidst declining selling prices in the industry.Several key products, including Repatha, EVENITY, and TEZSPIRE, contributed to the growth, with 16 products achieving double-digit sales increases and 14 products surpassing $1 billion in annualized sales.

Amgen: Diversification Through Newer Blockbusters & A Strengthening Late-Stage Pipeline Rewriting Its Growth Story!

United States

Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Amgen Inc (AMGN US)

Primer: Amgen (AMGN UW) - May 2026

Amgen's diversified portfolio, with 17 products annualizing over $1 billion in sales, provides a stable revenue base to offset patent...

αSK Primers

Downgrading Technology; Upgrading Energy and Health Care to Overweight; Caution Within A.I. Names

Downgrading Technology $XLK $SOXX $SMH; Upgrading Energy $XLE and Health Care $XLV to Overweight; Caution Within A.I. Names; Outside of A.I. areas,...

Vermilion Research

Amgen’s Obesity Drug May Crush Novo Nordisk & Lilly With Just Four Shots A Year!

Amgen has reignited investor interest in the obesity drug space with its latest update on MariTide, a GLP-1 agonist that could reshape the...

Baptista Research

Amgen Quietly Acquires UK Biotech—Is This a Pipeline Power Play?

Amgen Inc. has taken a bold step into the oncology innovation frontier with its acquisition of UK-based Dark Blue Therapeutics, a private biotech...

Baptista Research

Amgen: Diversification Through Newer Blockbusters & A Strengthening Late-Stage Pipeline Rewriting Its Growth Story!

Amgen reported notable financial results for Q3 2025 with revenue growth of 12% year-over-year, reaching $9.6 billion. The company's volume growth...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)